Literature DB >> 10889032

Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays.

S S Carroll1, V Sardana, Z Yang, A R Jacobs, C Mizenko, D Hall, L Hill, J Zugay-Murphy, L C Kuo.   

Abstract

The enzymatic activity of a C-terminally truncated form of the RNA-dependent RNA polymerase, termed NS5B(Delta21), of the hepatitis C virus (strain BK) has been investigated using both homopolymeric and heteropolymeric RNA templates. Incorporation of nucleotides into a heteropolymeric RNA template as catalyzed by NS5B(Delta21) is characterized by biphasic reaction time courses. At high concentrations of nucleoside triphosphate in reactions allowing a preincubation of NS5B(Delta21) and RNA template, an initial rapid phase of the reaction is followed by a slower linear phase. The amplitude of the first phase of the reaction varies directly with the concentration of the enzyme in the reaction. It is shown here that full-length copies of the template are produced during the first phase of the reaction. Our results reveal that NS5B(Delta21) is processive but only a small fraction, less than 1%, of the purified enzyme present participates productively in the reaction. Most importantly, the turnover number for the hepatitis C NS5B(Delta21) is comparable to those observed for other polymerases such as the HIV-1 reverse transcriptase. The combined results reconcile in part the apparent discrepancy of the low, observed specific activity of the purified enzyme and the rapid generation of HCV in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889032     DOI: 10.1021/bi991992s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.

Authors:  Daniel M Himmel; Stefan G Sarafianos; Sanjeewa Dharmasena; Mohammed M Hossain; Kessler McCoy-Simandle; Tatiana Ilina; Arthur D Clark; Jennifer L Knight; John G Julias; Patrick K Clark; Karsten Krogh-Jespersen; Ronald M Levy; Stephen H Hughes; Michael A Parniak; Eddy Arnold
Journal:  ACS Chem Biol       Date:  2006-12-20       Impact factor: 5.100

2.  Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

Authors:  Joanne E Tomassini; Krista Getty; Mark W Stahlhut; Sung Shim; Balkrishen Bhat; Anne B Eldrup; Thazha P Prakash; Steven S Carroll; Osvaldo Flores; Malcolm MacCoss; Daniel R McMasters; Giovanni Migliaccio; David B Olsen
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Quantitative analysis of the hepatitis C virus replication complex.

Authors:  Doris Quinkert; Ralf Bartenschlager; Volker Lohmann
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

Authors:  David B Olsen; Anne B Eldrup; Linda Bartholomew; Balkrishen Bhat; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; John F Fay; Osvaldo A Flores; Krista L Getty; Jay A Grobler; Robert L LaFemina; Eric J Markel; Giovanni Migliaccio; Marija Prhavc; Mark W Stahlhut; Joanne E Tomassini; Malcolm MacCoss; Daria J Hazuda; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  The Hepatitis C Virus NS5A Stimulates NS5B During In Vitro RNA Synthesis in a Template Specific Manner.

Authors:  Elizabeth M Quezada; Caroline M Kane
Journal:  Open Biochem J       Date:  2009-04-20

6.  Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA.

Authors:  Catherine Schuster; Catherine Isel; Isabelle Imbert; Chantal Ehresmann; Roland Marquet; Marie Paule Kieny
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design.

Authors:  Marcus Adrian Cheek; Mariam L Sharaf; Mikhail I Dobrikov; Barbara Ramsay Shaw
Journal:  Antiviral Res       Date:  2013-03-04       Impact factor: 5.970

8.  Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

Authors:  Licia Tomei; Sergio Altamura; Linda Bartholomew; Monica Bisbocci; Carolyn Bailey; Michele Bosserman; Antonella Cellucci; Eleonora Forte; Ilario Incitti; Laura Orsatti; Uwe Koch; Raffaele De Francesco; David B Olsen; Steven S Carroll; Giovanni Migliaccio
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405.

Authors:  Nathalie Scrima; Célia Caillet-Saguy; Michel Ventura; Déborah Harrus; Thérèse Astier-Gin; Stéphane Bressanelli
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

10.  Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.

Authors:  Julie A Heck; Angela M I Lam; Nirupama Narayanan; David N Frick
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.